Predicting the activity and toxicity of new psychoactive substances: A pharmaceutical industry perspective

Drug Testing and Analysis

Volumn 6, Issue 7-8, 2014, Pages 739-745

  Leach, Andrew G ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Computational chemistry; Illicit compounds; Pharmaceutical industry; Psychoactive drug

Indexed keywords

DRUG PRODUCTS; FORECASTING;

CLINICAL TRIAL; COMPUTATIONAL TECHNIQUE; EXPERIMENTAL TECHNIQUES; HUMAN BEING; ILLICIT COMPOUND; PHARMACEUTICAL INDUSTRY; PSYCHOACTIVE DRUG; SIDE EFFECT;

COMPUTATIONAL CHEMISTRY;

ACID; AMPHOLYTE; BASE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CYTOCHROME P450; MULTIDRUG RESISTANCE PROTEIN; PSYCHOTROPIC AGENT; PYRIDINIUM DERIVATIVE; TORCETRAPIB; STREET DRUG;

ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; LIPOPHILICITY; MEMBRANE PERMEABILITY; PREDICTION; PRIORITY JOURNAL; TOXICITY TESTING; BIOLOGICAL MODEL; COMPUTER SIMULATION; HUMAN;

COMPUTER SIMULATION; DRUG INDUSTRY; HUMANS; MODELS, BIOLOGICAL; PSYCHOTROPIC DRUGS; STREET DRUGS;

EID: 84904578763     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1593     Document Type: Article

References (80)

1. M. Herper . The truly staggering costs of inventing new drugs: the print version. Forbes. Available at: http://www.forbes.com/sites/matthewherper/2012/02/22/the-truly-staggering-cost-of-inventing-new-drugs-the-print-version/ [10 December 2013]
2. J.A. DiMasi, R.W. Hansen, H.G. Grabowski . The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22, 151.
3. S.M. Paul, D.S. Mytelka, C.T. Dunwiddie, C.C. Persinger, B.H. Munos, S.R. Lindborg, A.L. Schacht . How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9, 203.
4. D.J. Chandler . Something's got to give: psychiatric disease on the rise and novel drug development on the decline. Drug Discov. Today 2013, 18, 202.
5. S.J. Enna, M. Williams . Challenges in the search for drugs to treat central nervous system disorders. J. Pharmacol. Exp. Ther. 2009, 329, 404.
6. C. Wilkins, J. Sheridan, P. Adams, B. Russell, S. Ram, D. Newcombe . The new psychoactive substances regime in New Zealand: a different approach to regulation. J. Psychopharmacol. 2013, 27, 584.
7. M. Stocks, On medicinal chemistry, Sci-Ink Ltd, Great Britain, 2007.
8. G.L. Patrick, An introduction to medicinal chemistry, Oxford University Press, Oxford, 2009.
9. J.L. Medina-Franco, M.A. Giulianotti, G.S. Welmaker, R.A. Houghten . Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov. Today 2013, 18, 495.
10. C.S. Leung, S.S. Leung, J. Tirado-Rives, W.L. Jorgensen . Methyl effects on protein-ligand binding. J. Med. Chem. 2012, 55, 4489.
11. X. Hu, Y. Hu, M. Vogt, D. Stumpfe, J. Bajorath . MMP-Cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs. J. Chem. Inf. Model. 2012, 52, 1138.
12. Y. Hu, J. Bajorath . Introduction of target cliffs as a concept to identify and describe complex molecular selectivity patterns. J. Chem. Inf. Model. 2013, 53, 545.
13. Y. Hu, J. Bajorath . Extending the activity cliff concept: structural categorization of activity cliffs and systematic identification of different types of cliffs in the ChEMBL database. J. Chem. Inf. Model. 2012, 52, 1806.
14. D. Stumpfe, J. Bajorath . Exploring activity cliffs in medicinal chemistry. J. Med. Chem. 2012, 55, 2932.
15. Y. Hu, J. Bajorath . Compound promiscuity: what can we learn from current data? Drug Discov. Today 2013, 18, 644.
16. A.L. Hopkins . Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4, 682.
17. A. Koutsoukas, B. Simms, J. Kirchmair, P.J. Bond, A.V. Whitmore, S. Zimmer, M.P. Young, J.L. Jenkins, M. Glick, R.C. Glen, A. Bender . From in silico target prediction to multi-target drug design: current databases, methods and applications. J. Proteomics 2011, 74, 2554.
18. M.H. Baumann, J.S. Partilla, K.R. Lehner, E.B. Thorndike, A.F. Hoffman, M. Holy, R.B. Rothman, S.R. Goldberg, C.R. Lupica, H.H. Sitte, S.D. Brandt, S.R. Tella, N.V. Cozzi, C.W. Schindler . Powerful cocaine-like actions of 3, 4-Methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 2013, 38, 552.
19. M.H. Baumann, M.A. Ayestas Jr, J.S. Partilla, J.R. Sink, A.T. Shulgin, P.F. Daley, S.D. Brandt, R.B. Rothman, A.E. Ruoho, N.V. Cozzi . The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37, 1192.
20. N.V. Cozzi, S.D. Brandt, P.F. Daley, J.S. Partilla, R.B. Rothman, A. Tulzer, H.H. Sitte, M.H. Baumann . Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs. Eur. J. Pharmacol. 2013, 699, 180.
21. H. Yu, J. Chen, X. Xu, Y. Li, H. Zhao, Y. Fang, X. Li, W. Zhou, W. Wang, Y. Wang . A Systematic Prediction of Multiple Drug-Target Interactions from Chemical, Genomic, and Pharmacological Data. PLoS ONE 2012, 7, e37608.
22. V. Cherezov, D.M. Rosenbaum, M.A. Hanson, S.G. Rasmussen, F.S. Thian, T.S. Kobilka, H.J. Choi, P. Kuhn, W.I. Weis, B.K. Kobilka, R.C. Stevens . High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318, 1258.
23. E.Y. Chien, W. Liu, Q. Zhao, V. Katritch, G.W. Han, M.A. Hanson, L. Shi, A.H. Newman, J.A. Javitch, V. Cherezov, R.C. Stevens . Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330, 1091.
24. D. Wacker, C. Wang, V. Katritch, G.W. Han, X.P. Huang, E. Vardy, J.D. McCorvy, Y. Jiang, M. Chu, F.Y. Siu, W. Liu, H.E. Xu, V. Cherezov, B.L. Roth, R.C. Stevens . Structural features for functional selectivity at serotonin receptors. Science 2013, 340, 615.
25. D. Wacker, G. Fenalti, M.A. Brown, V. Katritch, R. Abagyan, V. Cherezov, R.C. Stevens . Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J. Am. Chem. Soc. 2010, 132, 11443.
26. H. Wu, D. Wacker, M. Mileni, V. Katritch, G.W. Han, E. Vardy, W. Liu, A.A. Thompson, X.P. Huang, F.I. Carroll, S.W. Mascarella, R.B. Westkaemper, P.D. Mosier, B.L. Roth, V. Cherezov, R.C. Stevens . Structure of the human kappa-opioid receptor in complex with JDTic. Nature 2012, 485, 327.
27. H. Wang, A. Goehring, K.H. Wang, A. Penmatsa, R. Ressler, E. Gouaux . Structural basis for action by diverse antidepressants on biogenic amine transporters. Nature 2013, 503, 141.
28. K. Azzaoui, J. Hamon, B. Faller, S. Whitebread, E. Jacoby, A. Bender, J.L. Jenkins, L. Urban . Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2007, 2, 874.
29. D.W. Young, A. Bender, J. Hoyt, E. McWhinnie, G.W. Chirn, C.Y. Tao, J.A. Tallarico, M. Labow, J.L. Jenkins, T.J. Mitchison, Y. Feng . Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol. 2008, 4, 59.
30. A. Bender, J. Scheiber, M. Glick, J.W. Davies, K. Azzaoui, J. Hamon, L. Urban, S. Whitebread, J.L. Jenkins . Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007, 2, 861.
31. J. Scheiber, B. Chen, M. Milik, S.C. Sukuru, A. Bender, D. Mikhailov, S. Whitebread, J. Hamon, K. Azzaoui, L. Urban, M. Glick, J.W. Davies, J.L. Jenkins . Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J. Chem. Inf. Model. 2009, 49, 308.
32. M.J. Waring, I.J. Brogan, M. Coghlan, C. Johnstone, H.B. Jones, B. Leighton, D. McKerrecher, K.G. Pike, G.R. Robb . Overcoming retinoic acid receptor-[small alpha] based testicular toxicity in the optimisation of glucokinase activators. Med. Chem. Commun. 2011, 2, 771.
33. J.E. Floettmann, L.K. Buckett, A.V. Turnbull, T. Smith, C. Hallberg, A. Birch, D. Lees, H.B. Jones . ACAT-selective and Nonselective DGAT1 Inhibition: Adrenocortical Effects--A Cross-species Comparison. Toxicol. Pathol. 2013, 41, 941.
34. Y. Hu, J. Bajorath . Promiscuity profiles of bioactive compounds: potency range and difference distributions and the relation to target numbers and families. Med. Chem. Commun. 2013, 4, 1196.
35. N.P. Franks . Molecular targets underlying general anaesthesia. Br. J. Pharmacol. 2006, 147(Suppl 1), S72.
36. M.C. Sanguinetti, M. Tristani-Firouzi . hERG potassium channels and cardiac arrhythmia. Nature (London, U. K.) 2006, 440, 463.
37. ICH S2(R1) 2011. Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva.
38. A.P. Li . Drug-drug interactions in pharmaceutical development, Wiley-Interscience, New York; Chichester, 2008.
39. S. Ekins, J. Berbaum, R.K. Harrison . Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab. Dispos. 2003, 31, 1077.
40. M.P. Gleeson . Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51, 817.
41. C.A. Kemp, J.U. Flanagan, A.J. van Eldik, J. Marechal, C.R. Wolf, G.C.K. Roberts, M.J.I. Paine, M.J. Sutcliffe . Validation of model of cytochrome P450 2D6: An in silico tool for predicting metabolism and inhibition. J. Med. Chem. 2004, 47, 5340.
42. I. Shamovsky, C. de Graaf, L. Alderin, M. Bengtsson, H. Bladh, L. Borjesson, S. Connolly, H.J. Dyke, M. van den Heuvel, H. Johansson, B. Josefsson, A. Kristoffersson, T. Linnanen, A. Lisius, R. Mannikko, B. Norden, S. Price, L. Ripa, D. Rognan, A. Rosendahl, M. Skrinjar, K. Urbahns . Increasing selectivity of CC chemokine receptor 8 antagonists by engineering nondesolvation related interactions with the intended and off-target binding sites. J. Med. Chem. 2009, 52, 7706.
43. H.H.F. Refsgaard, B.F. Jensen, I.T. Christensen, N. Hagen, P.B. Brockhoff . In silico prediction of cytochrome P450 inhibitors. Drug Dev. Res. 2006, 67, 417.
44. A.O. Aptula, M.T.D. Cronin . Prediction of hERG K+ blocking potency: Application of structural knowledge. SAR QSAR Environ. Res. 2004, 15, 399.
45. S. Ekins . In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem. Soc. Trans. 2003, 31, 611.
46. C. Jamieson, E.M. Moir, Z. Rankovic, G. Wishart . Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. 2006, 49, 5029.
47. J.S. Mitcheson, J. Chen, M. Lin, C. Culberson, M.C. Sanguinetti . A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 12329.
48. U. Zachariae, F. Giordanetto, A.G. Leach . Side Chain Flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. J. Med. Chem. 2009, 52, 4266.
49. M.J. Waring, C. Johnstone . A quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett. 2007, 17, 1759.
50. S.G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P.M. Harrell, Y.T. Trinh, Q. Zhang, I.L. Urbatsch, G. Chang . Structure of P-Glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323, 1718.
51. S. Gibbons . 'Legal highs' - novel and emerging psychoactive drugs: a chemical overview for the toxicologist. Clin. Toxicol. (Phila.) 2012, 50, 15.
52. Chemspider website. Available at: http://www.chemspider.com [10 December 2013]
53. M.J. Waring . Lipophilicity in drug discovery. Expert Opin. Drug Discovery 2010, 5, 235.
54. T. Bueters, B.A. Ploeger, S.A. Visser . The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discov. Today 2013, 18, 853.
55. I. Kola, J. Landis . Opinion: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004, 3, 711.
56. C. Li, B. Liu, J. Chang, T. Groessl, M. Zimmerman, Y.Q. He, J. Isbell, T. Tuntland . A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery. Drug Discov. Today 2013, 18, 71.
57. S.A. Hitchcock, L.D. Pennington . Structure-brain exposure relationships. J. Med. Chem. 2006, 49, 7559.
58. W. McCoull, P. Barton, A. Broo, A.J.H. Brown, D.S. Clarke, G. Coope, R.D.M. Davies, A.G. Dossetter, E.E. Kelly, L. Knerr, P. MacFaul, J.L. Holmes, N. Martin, J.E. Moore, D. Morgan, C. Newton, K. Osterlund, G.R. Robb, E. Rosevere, N. Selmi, S. Stokes, T.S. Svensson, V.B.K. Ullah, E.J. Williams . Identification of pyrazolo-pyrimidinones as GHS-R1a antagonists and inverse agonists for the treatment of obesity. Med. Chem. Commun. 2013, 4, 456.
59. S. Yiu, E.E. Knaus . Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system. J. Med. Chem. 1996, 39, 4576.
60. A.A. Bhattacharya, T. Grune, S. Curry . Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 2000, 303, 721.
61. S. Curry . Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab. Pharmacokinet. 2009, 24, 342.
62. M.L. Hall, W.L. Jorgensen, L. Whitehead . Automated ligand- and structure-based protocol for in silico prediction of human serum albumin binding. J. Chem. Inf. Model. 2013, 53, 907.
63. J.A. Sheps . Through a mirror, differently. Science 2009, 323, 1679.
64. I.G. Denisov, T.M. Makris, S.G. Sligar, I. Schlichting . Structure and chemistry of cytochrome P 450. Chem. Rev. 2005, 105, 2253.
65. J. Gabrielsson, O. Fjellstroem, J. Ulander, M. Rowley, P.H. Van Der Graaf . Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2011, 11, 404.
66. B.J. Schmidt, J.A. Papin, C.J. Musante . Mechanistic systems modeling to guide drug discovery and development. Drug Discov. Today 2013, 18, 116.
67. J.D. Hughes, J. Blagg, D.A. Price, S. Bailey, G.A. DeCrescenzo, R.V. Devraj, E. Ellsworth, Y.M. Fobian, M.E. Gibbs, R.W. Gilles, N. Greene, E. Huang, T. Krieger-Burke, J. Loesel, T. Wager, L. Whiteley, Y. Zhang . Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008, 18, 4872.
68. A. Sivarajah, S. Collins, M.R. Sutton, N. Regan, H. West, M. Holbrook, N. Edmunds . Cardiovascular safety assessments in the conscious telemetered dog: utilisation of super-intervals to enhance statistical power. J. Pharmacol. Toxicol. Methods 2010, 62, 12.
69. F.D. Sistare, D. Morton, C. Alden, J. Christensen, D. Keller, S.D. Jonghe, R.D. Storer, M.V. Reddy, A. Kraynak, B. Trela, J.G. Bienvenu, S. Bjurstrom, V. Bosmans, D. Brewster, K. Colman, M. Dominick, J. Evans, J.R. Hailey, L. Kinter, M. Liu, C. Mahrt, D. Marien, J. Myer, R. Perry, D. Potenta, A. Roth, P. Sherratt, T. Singer, R. Slim, K. Soper, R. Fransson-Steen, J. Stoltz, O. Turner, S. Turnquist, M. van Heerden, J. Woicke, J.J. DeGeorge . An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol. Pathol. 2011, 39, 716.
70. I. Ijjaali, C. Barrere, J. Nargeot, F. Petitet, E. Bourinet . Ligand-based virtual screening to identify new T-type calcium channel blockers. Channels (Austin) 2007, 1, 300.
71. M.R. Doddareddy, H. Choo, Y.S. Cho, H. Rhim, H.Y. Koh, J.H. Lee, S.W. Jeong, A.N. Pae . 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg. Med. Chem. 2007, 15, 1091.
72. M.R. Doddareddy, H.K. Jung, J.H. Cha, Y.S. Cho, H.Y. Koh, M.H. Chang, A.N. Pae . 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA. Bioorg. Med. Chem. 2004, 12, 1613.
73. G.M. Lipkind, H.A. Fozzard . Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the L-type Ca2+ channel. Mol. Pharmacol. 2003, 63, 499.
74. P. Bergson, G. Lipkind, S.P. Lee, M.E. Duban, D.A. Hanck . Verapamil block of T-type calcium channels. Mol. Pharmacol. 2011, 79, 411.
75. D. Muthas, S. Boyer, C. Hasselgren . A critical assessment of modeling safety-related drug attrition. Med. Chem. Commun. 2013, 4, 1058.
76. C. Hansch, A. Leo, S.H. Unger, K.H. Kim, D. Nikaitani, E.J. Lien . Aromatic substituent constants for structure-activity correlations. J. Med. Chem. 1973, 16, 1207.
77. P.D. Leeson, B. Springthorpe . The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discovery 2007, 6, 881.
78. P.W. Kenny, C.A. Montanari . Inflation of correlation in the pursuit of drug-likeness. J. Comput. Aided Mol. Des. 2013, 27, 1.
79. L. Vegner, A. Peragovics, L. Tombor, B. Jelinek, P. Czobor, A. Bender, Z. Simon, A. Malnasi-Csizmadia . Experimental confirmation of new drug-target interactions predicted by drug profile matching. J. Med. Chem. 2013, 56, 8377-8388.
80. F. Mohd Fauzi, A. Koutsoukas, A. Cunningham, A. Gallegos, R. Sedefov, A. Bender . Computer-aided (in silico) approaches in the mode-of-action analysis and safety assessment of Ostarine and 4-methylamphetamine. Hum. Psychopharmacol. 2013, 28, 365.